Analysis of 677 adult AML patients undergoing allogeneic stem cell transplantation (alloHSCT) with post-transplant cyclophosphamide (PTCy) in first complete remission.
Comparison between patients achieving CR1 after one induction chemotherapy course versus those requiring two courses.
Similar overall survival, leukemia-free survival, and GVHD-free/relapse-free survival despite higher relapse incidence in the two-induction group.
Findings support alloHSCT with PTCy as effective regardless of induction course number needed for remission.
